viewFrontier IP Group PLC

Frontier IP eyes increasing maturity across portfolio companies


The investment firm focuses on providing consultancy services to universities and other research organisations to help them commercialise any intellectual property arising from their research

Investment papers and laptop

Quick facts: Frontier IP Group PLC

Price: 57.385 GBX

Market: AIM
Market Cap: £24.35 m

• Investment firm focused on commercialisation of IPs
• Provides services to university and research organisations to brink products to market
• Takes equity stakes in spin-out companies

What Frontier IP does

Frontier IP Group Plc (LON:FIPP) is an investment and asset management company that focuses on providing consultancy services to universities and other research organisations to help them commercialise any intellectual property (IP) arising from their research.

The group aims to grow its value by taking equity stakes in any spin-out companies that arise from the commercialisation of IPs.

What it owns

As of 7 May 2019, Frontier’s portfolio consists of;

Alusid – Develops SilicaStone, a stone substitute made from recycled industrial waste

Nandi Proteins – Researches technology to improve the functional properties of proteins used in food-making such as eggs and whey

The Vaccine Group – Makes vaccines for animals to prevent them from passing on illnesses to humans such as Ebola, SARS, AIDS, Marburg, and swine and bird flu

Tarsis Technology – Develops tech that allows controlled delivery of active ingredients using metal-organic frameworks

Porexpert – Provides software to help model porous structures and test their properties

Pulsiv Solar – Develops technology to increase energy efficiency in solar farms as well as power converters for TVs, mobile phones and other electronics

Exscientia – Uses artificial intelligence to automate the design of pharmaceutical drugs

Cambridge Simulation Solutions – Provides methods of simulating and controlling complex discontinuous processes, such as how neural transmitters work in the brain

Amprologix – Aims to introduce new classes of antibiotics to help combat antimicrobial resistance to treatments

Molendotech – Provides a rapid assay to screen water for faecal contamination and other harmful bacteria without the need for laboratory testing

Fieldwork Robotics – Develops robot technology to harvest fruits and vegetables

NTPE – Develops a technology to print electronic circuits and semiconductors onto paper

Inflexion points

• Frontier IP was selected as a partner for Emporia4KT, a €2.2mln EU-backed project to boost research into the continent’s marine economy

• Portfolio firm Pulsiv Solar has signed an agreement with German engineering giant Bosch to optimise the design of its energy-efficient solar micro-inverter prototype

• Exscientia signed a three-year collaboration deal with US biotech giant Celgene Corp (NASDAQ:CELG) which included an upfront payment of US$25mln

• In its latest set of half-year results, Frontier reported that the value of its portfolio had increased to £11.5mln from £9.1mln in the prior six months

Blue Sky

In its interim results at the end of March, Frontier IP’s chief executive Neil Crabb said the firm was seeing “strong interest” in its portfolio from a “growing number” of industry leading firms and that the momentum generated in the first-half had continued into the second, with Frontier’s performance for the full year expected to be “ahead of management expectations”.

“The first half of the year provides further evidence our approach is gaining traction with stakeholders,” Crabb said.

Speaking to Proactive in April, he added that going forward the company will “continue to build out the portfolio” and that the company was looking forward to “more of the same” from its companies.

“We’re seeing an increasingly mature portfolio, the formula is working…the growth of that portfolio in terms of both its individual constituents and the scale we think sets us up very well to deliver good results in the future”.

In terms of additions to the portfolio, Crabb says that there is “more than enough opportunity”, however striving for more organic growth doing the same thing is “what it’s all about”.

With shares trading at 86p as of 7 May 2019, Frontier IP has a market cap of £36.2mln.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...



Frontier IP focused on further industrial engagement across portfolio

Neil Crabb, chief executive of Frontier IP Group Plc (LON:FIPP) caught up with Proactive's Andrew Scott following the release of their half-year report. Frontier’s portfolio includes AI drug researcher Exscientia which secured a €15mln strategic investment from drug discovery company...

on 29/3/18

4 min read